Log in

Kadmon Stock Forecast, Price & News

-0.06 (-1.56 %)
(As of 09/24/2020 12:00 AM ET)
Today's Range
Now: $3.79
50-Day Range
MA: $4.31
52-Week Range
Now: $3.79
Volume2.29 million shs
Average Volume2.33 million shs
Market Capitalization$648.61 million
P/E RatioN/A
Dividend YieldN/A
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. The company markets and distributes products in various therapeutic areas, including ribavirin products for chronic hepatitis C virus infection; and distributes products in various therapeutic areas, including tetrabenazine for the treatment of chorea associated with Huntington's disease. Its lead product candidates include KD025, an inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical studies for the treatment of chronic graft-versus-host, fibrotic, and psoriasis diseases; KD045, an ROCK inhibitor for the treatment of fibrotic diseases; KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer; and KD034, a generic formulation of trientine hydrochloride for the treatment of Wilson's disease, a genetic liver disease. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease (PKD) and autosomal recessive PKD. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Symphony Evolution, Inc.; Nano Terra, Inc.; Dyax Corp.; Zydus Pharmaceuticals USA, Inc.; and Jinghua Pharmaceutical Group Co., Ltd. The company is headquartered in New York, New York.
Read More
Kadmon logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations



Sales & Book Value

Annual Sales$5.09 million
Book Value$0.95 per share


Net Income$-61,370,000.00
Net Margins-1,105.49%


Market Cap$648.61 million
Next Earnings Date11/5/2020 (Estimated)
-0.06 (-1.56 %)
(As of 09/24/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KDMN News and Ratings via Email

Sign-up to receive the latest news and ratings for KDMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kadmon (NYSE:KDMN) Frequently Asked Questions

How has Kadmon's stock price been impacted by COVID-19 (Coronavirus)?

Kadmon's stock was trading at $3.48 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KDMN shares have increased by 8.9% and is now trading at $3.79.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Kadmon?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kadmon in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kadmon

When is Kadmon's next earnings date?

Kadmon is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Kadmon

How were Kadmon's earnings last quarter?

Kadmon Holdings Inc (NYSE:KDMN) posted its quarterly earnings data on Thursday, August, 6th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.04. The firm earned $0.45 million during the quarter, compared to analyst estimates of $0.55 million. Kadmon had a negative net margin of 1,105.49% and a negative return on equity of 138.49%.
View Kadmon's earnings history

What price target have analysts set for KDMN?

5 equities research analysts have issued 1 year target prices for Kadmon's stock. Their forecasts range from $8.00 to $25.00. On average, they anticipate Kadmon's share price to reach $12.60 in the next year. This suggests a possible upside of 232.5% from the stock's current price.
View analysts' price targets for Kadmon

Who are some of Kadmon's key competitors?

What other stocks do shareholders of Kadmon own?

Who are Kadmon's key executives?

Kadmon's management team includes the following people:
  • Dr. Harlan W. Waksal, Pres, CEO & Director (Age 66)
  • Mr. Steven Meehan, Exec. VP & CFO (Age 54)
  • Mr. Steven N. Gordon, Chief Admin., Compliance & Legal Officer, Exec. VP & Gen. Counsel (Age 51)
  • Ms. Cynthia L. Schwalm, Director (Age 59)
  • Mr. Kyle Carver, Controller & Principal Accounting Officer

When did Kadmon IPO?

(KDMN) raised $101 million in an IPO on Wednesday, July 27th 2016. The company issued 5,600,000 shares at a price of $16.00-$20.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and JMP Securities and H.C. Wainwright & Co. were co-managers.

What is Kadmon's stock symbol?

Kadmon trades on the New York Stock Exchange (NYSE) under the ticker symbol "KDMN."

Who are Kadmon's major shareholders?

Kadmon's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.73%), Third Point LLC (4.44%), Avidity Partners Management LP (3.76%), Point72 Asset Management L.P. (3.11%), Goldman Sachs Group Inc. (2.91%) and Two Sigma Advisers LP (1.19%). Company insiders that own Kadmon stock include Cynthia Schwalm, Harlan Waksal and Perceptive Advisors Llc.
View institutional ownership trends for Kadmon

Which major investors are selling Kadmon stock?

KDMN stock was sold by a variety of institutional investors in the last quarter, including Third Point LLC, Ikarian Capital LLC, UBS Group AG, Healthcare of Ontario Pension Plan Trust Fund, Verition Fund Management LLC, EAM Investors LLC, Vanguard Group Inc., and SG Americas Securities LLC.
View insider buying and selling activity for Kadmon

Which major investors are buying Kadmon stock?

KDMN stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Avidity Partners Management LP, Goldman Sachs Group Inc., Cormorant Asset Management LP, Monashee Investment Management LLC, Marshall Wace North America L.P., Assenagon Asset Management S.A., and Great Point Partners LLC. Company insiders that have bought Kadmon stock in the last two years include Cynthia Schwalm, Harlan Waksal, and Perceptive Advisors Llc.
View insider buying and selling activity for Kadmon

How do I buy shares of Kadmon?

Shares of KDMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kadmon's stock price today?

One share of KDMN stock can currently be purchased for approximately $3.79.

How big of a company is Kadmon?

Kadmon has a market capitalization of $648.61 million and generates $5.09 million in revenue each year. The company earns $-61,370,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis. Kadmon employs 116 workers across the globe.

What is Kadmon's official website?

The official website for Kadmon is www.kadmon.com.

How can I contact Kadmon?

Kadmon's mailing address is 450 East 29th Street, New York NY, 10016. The company can be reached via phone at 833-900-5366 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.